BridgeBio shares have ‘clear path’ to $90s, says JPMorgan

JPMorgan views BridgeBio (BBIO) as a top idea and sees a buying opportunity at current share levels. The stock closed Monday down 4% to $64.686. The firm sees a “clear path” to the $90s to triple-digits per share level, due to continued Attruby launch momentum and BridgeBio’s sales diversification via its late-stage pipeline. JPMorgan says the company did not push back on its assessment that patient additions on a weekly basis grew quarter-over-quarter in Q1 and stressed volume strength in the treatment naive setting.